In Reply We thank Chun et al for their letter and interest in the CONVERT trial1 and the early stage subgroup analysis2 published in JAMA Oncology. To date, most improvements in limited-stage small cell lung cancer management have been in the area of radiotherapy, highlighting its integral role in the management of this disease. We agree with Chun and colleagues on the importance of high-quality evidence from well-designed and executed randomized trials in small cell lung cancer. We eagerly await results from the CALGB 30610/NRG Oncology-RTOG 0538 trial (NCT00632853), which will further inform the care of limited-stage small cell lung cancer.
Salem A, Faivre-Finn C. Time to Change the Limited-Stage Paradigm for Small Cell Lung Cancer?—In Reply. JAMA Oncol. Published online June 20, 20195(8):1229–1230. doi:10.1001/jamaoncol.2019.1332
Browse and subscribe to JAMA Network podcasts!
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: